Boston Scientific Corp (BSX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2015 | 12-2014 | 12-2013 | 12-2012 | 12-2011 | |
| Sales | 7,477,000 | 7,380,000 | 7,143,000 | 7,249,000 | 7,622,000 |
| Cost of Goods | 2,173,000 | 2,210,000 | 2,174,000 | 2,349,000 | 2,659,000 |
| Gross Profit | 5,304,000 | 5,170,000 | 4,969,000 | 4,900,000 | 4,963,000 |
| Operating Expenses | 5,587,000 | 5,471,000 | 4,849,000 | 8,768,000 | 4,059,000 |
| Operating Income | -283,000 | -301,000 | 120,000 | -3,868,000 | 904,000 |
| Interest Expense | 284,000 | 216,000 | 324,000 | 261,000 | 281,000 |
| Other Income | -83,000 | 8,000 | -19,000 | 22,000 | 19,000 |
| Pre-tax Income | -650,000 | -509,000 | -223,000 | -4,107,000 | 642,000 |
| Income Tax | -411,000 | -390,000 | -102,000 | -39,000 | 201,000 |
| Net Income Continuous | -239,000 | -119,000 | -121,000 | -4,068,000 | 441,000 |
| Net Income | $-239,000 | $-119,000 | $-121,000 | $-4,068,000 | $441,000 |
| EPS Basic Total Ops | -0.18 | -0.09 | -0.09 | -2.89 | 0.29 |
| EPS Basic Continuous Ops | -0.18 | -0.09 | -0.09 | -2.89 | 0.29 |
| EPS Diluted Total Ops | -0.18 | -0.09 | -0.09 | -2.89 | 0.29 |
| EPS Diluted Continuous Ops | -0.18 | -0.09 | -0.09 | -2.89 | 0.29 |
| EBITDA(a) | $505,000 | $619,000 | $1,285,000 | $1,307,000 | $2,339,000 |